EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study

Mariam M Fakhry iD, Amr A Mattar iD, Marwa Alsulaimany iD, Ebtesam M Al-Olayan iD, Sara T Al-Rashood, Hatem A Abdel-Aziz iD

Molecules · 06.11.2023 · 28 (21) · 7455

DOI: 10.3390/molecules28217455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 06.11.2023. Verfasst von Mariam M Fakhry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Researchers Supporting Project number (RSP-2023/103), King Saud University, Riyadh, Saudi Arabia., King Saud University, Riyadh, Saudi Arabia..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of thiazolyl-pyrazoline derivatives (4a–d, 5a–d 6a, b, 7a–d, 8a, b, and 10a, b) have been designed and synthesized through the combination of thiazole and pyrazoline moieties, starting from the key building blocks pyrazoline carbothioamides (1a–b). These eighteen derivatives have been designed as anticipated EGFR/HER2 dual inhibitors. The efficacy of the developed compounds in inhibiting cell proliferation was assessed using the breast cancer MCF-7 cell line. Among the new synthesized thiazolyl-pyrazolines, compounds 6a, 6b, 10a, and 10b displayed potent anticancer activity toward MCF-7 with IC50 = 4.08, 5.64, 3.37, and 3.54 µM, respectively, when compared with lapatinib (IC50 = 5.88 µM). In addition, enzymatic assays were also run for the most cytotoxic compounds (6a and 6b) toward EGFR and HER2 to demonstrate their dual inhibitory activity. They revealed promising inhibition potency against EGFR with IC50 = 0.024, and 0.005 µM, respectively, whereas their IC50 = 0.047 and 0.022 µM toward HER2, respectively, compared with lapatinib (IC50 = 0.007 and 0.018 µM). Both compounds 6a and 10a induced apoptosis by arresting the cell cycle of the MCF-7 cell line at the G1 and G1/S phases, respectively. Molecular modeling studies for the promising candidates 6a and 10a showed that they formed the essential binding with the crucial amino acids for EGFR and HER2 inhibition, supporting the in vitro assay results. Furthermore, ADMET study predictions were carried out for the compounds in the study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAntineoplastic AgentsHumansMolecular StructureStructure-Activity RelationshipLapatinibDrug Screening Assays, AntitumorCell ProliferationErbB ReceptorsMolecular Docking SimulationCell Line, Tumor

Stichwörter der Autor:innen

EGFRHER2anti-cancerapoptosiscell cyclethiazolyl-pyrazoline

Substanzen

LapatinibProtein Kinase InhibitorsAntineoplastic AgentsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
  • Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina 42353, Saudi Arabia.
  • Department of Zoology, College of Science, King Saud University, Riyadh 11495, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  • Applied Organic Chemistry Department, National Research Center, Cairo 12622, Egypt.

ORCID-Profile: Mariam M Fakhry, Amr A Mattar, Marwa Alsulaimany, Ebtesam M Al-Olayan, Hatem A Abdel-Aziz

Förderung

  • Researchers Supporting Project number (RSP-2023/103), King Saud University, Riyadh, Saudi Arabia.
  • King Saud University, Riyadh, Saudi Arabia.

Zitieren

APA

Fakhry, M. M., Mattar, A. A., Alsulaimany, M., Al-Olayan, E. M., Al-Rashood, S. T., & Abdel-Aziz, H. A. (2023). New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study. Molecules, 28(21), 7455. https://doi.org/10.3390/molecules28217455

Vancouver

Fakhry MM, Mattar AA, Alsulaimany M, Al-Olayan EM, Al-Rashood ST, Abdel-Aziz HA. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study. Molecules. 2023;28(21):7455. doi:10.3390/molecules28217455

BibTeX
@article{Fakhry2023,
  author = {Fakhry, Mariam M and Mattar, Amr A and Alsulaimany, Marwa and Al-Olayan, Ebtesam M and Al-Rashood, Sara T and Abdel-Aziz, Hatem A},
  title = {New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {21},
  pages = {7455},
  doi = {10.3390/molecules28217455}
}
Kostenlos starten →